5JD0 Stock Overview
Through its subsidiary, ExpreS2ion Biotechnologies ApS, researches and develops preventive and therapeutic vaccine products in the Nordics and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
ExpreS2ion Biotech Holding AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 1.60 |
| 52 Week High | SEK 18.26 |
| 52 Week Low | SEK 1.60 |
| Beta | 1.65 |
| 11 Month Change | -26.20% |
| 3 Month Change | -22.33% |
| 1 Year Change | -45.50% |
| 33 Year Change | -99.17% |
| 5 Year Change | n/a |
| Change since IPO | -98.07% |
Recent News & Updates
Recent updates
Shareholder Returns
| 5JD0 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -11.1% | 0.8% | 0.8% |
| 1Y | -45.5% | -18.3% | 8.6% |
Return vs Industry: 5JD0 underperformed the German Biotechs industry which returned -18.3% over the past year.
Return vs Market: 5JD0 underperformed the German Market which returned 8.6% over the past year.
Price Volatility
| 5JD0 volatility | |
|---|---|
| 5JD0 Average Weekly Movement | 39.9% |
| Biotechs Industry Average Movement | 6.5% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.9% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 5JD0's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 5JD0's weekly volatility has decreased from 52% to 40% over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 18 | Bent Frandsen | www.expres2ionbio.com |
ExpreS2ion Biotech Holding AB (publ), through its subsidiary, ExpreS2ion Biotechnologies ApS, researches and develops preventive and therapeutic vaccine products in the Nordics and internationally. The company’s lead asset is ES2B-C001, a therapeutic vaccine for breast cancer that targets the human epidermal growth factor receptor 2 receptor. It is also developing ES2B-I002, a cytomegalovirus vaccine candidate to treat infectious diseases.
ExpreS2ion Biotech Holding AB (publ) Fundamentals Summary
| 5JD0 fundamental statistics | |
|---|---|
| Market cap | €3.40m |
| Earnings (TTM) | -€2.95m |
| Revenue (TTM) | €687.72k |
4.9x
P/S Ratio-1.2x
P/E RatioIs 5JD0 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 5JD0 income statement (TTM) | |
|---|---|
| Revenue | SEK 7.93m |
| Cost of Revenue | SEK 4.07m |
| Gross Profit | SEK 3.86m |
| Other Expenses | SEK 37.86m |
| Earnings | -SEK 34.00m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Feb 06, 2025
| Earnings per share (EPS) | -16.19 |
| Gross Margin | 48.66% |
| Net Profit Margin | -428.76% |
| Debt/Equity Ratio | 0.5% |
How did 5JD0 perform over the long term?
See historical performance and comparison